Evidence map›Paper›PMID 40244489›Full record

ArticleInflammopharmacology2025

The neuroprotective potential of Gerbera Jamesonii in a neuronal demyelination rat model through the modulation of interleukins, cyclooxygenase and tumor necrosis factor-α.

Shazia Anwer Bukhari, Haleema Sadia, Zunera Chauhdary

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shazia Anwer BukhariDepartment of Biochemistry, Government College University Faisalabad, , Faisalabad, Pakistan.
Haleema SadiaDepartment of Biochemistry, Government College University Faisalabad, , Faisalabad, Pakistan.
Zunera ChauhdaryDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad, Pakistan. zunerach@yahoo.com.ORCID http://orcid.org/0000-0003-4191-8697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis is characterized by the demyelination of neurons, which is a chronic inflammatory disease of the central nervous system. This autoimmune disorder occurs due to an imbalance in the body's immune system as a result of uncontrolled oxidative stress. The B and T lymphocytes cross the blood-brain barrier and destroy the myelin sheath. Multiple sclerosis is one of the most common causes of disability in young adults affecting approximately 3 million individuals worldwide. Among them, females are considered at higher risk than males. It disrupts the normal functioning of life badly and major symptoms include loss of sensation, poor vision, impaired hearing, and cognitive abnormalities. Several treatments and drugs have been used to treat this medical condition, but they pose serious side effects also. So, the need of the hour is to explore such natural bioactive compounds that have neuroprotective properties, thus leading to the treatment of neurodegenerative disorders. Among various plants with medicinal properties, Gerbera jamesonii is a plant that exhibits antioxidant, anti-inflammatory, and neuroprotective properties. To enhance its therapeutic potential, this study aimed to load its ethanolic extract into solid-lipid nanoparticle formulations (SLNs), which is an innovative approach for treatment because nanoparticles provide effective targeted drug delivery due to their extremely small size. Solid-lipid nanoparticles were prepared using the emulsification-solvent evaporation method. For experimental design, 30 Wistar rats were randomly divided into seven groups (n = 10): normal, demyelination disease model, standard drugs, dimethyl fumarate and fingolimod (FTY 720) 15 mg/kg, and three treatment groups: GJ-NPs 250 mg/kg, 500 mg/kg, and 750 mg/kg. Prior to treatment, 0.2% cuprizone solution was prepared for the induction of multiple sclerosis in all groups except the normal group for 42 days. Biochemical analyses such as determination of inflammatory biomarkers and antioxidant enzymes were performed. The plant extract was subjected to HPLC to examine its phenolic compounds which are active in healing neurodegeneration. Physiological changes in rats were observed such as motor dysfunction and anxiety-like behavior caused by cuprizone. Behavioral tests showed significant improvement of motor function, muscular coordination, and enhanced cognitive abilities in the treatment groups as compared to the demyelination disease model. Histopathology of the rat brain regions showed significant differences in the normal and demyelinated areas. The results showed that GJ-NPs treated demyelination, modulating oxidative stress manifested by pro-inflammatory cytokines TNF-α, IL-6, AβPP, α-synuclein, NF-

Indexed as

Demyelinating DiseasesInterleukinsNeuroprotective AgentsPlant ExtractsTumor Necrosis Factor-alphaAnimalsDisease Models, AnimalFemaleMaleMultiple SclerosisNanoparticlesNeuronsOxidative StressRatsRats, WistarInterleukinsNeuroprotective AgentsPlant ExtractsTumor Necrosis Factor-alphaDemyelinationEmulsification–solvent evaporation methodGerbera jamesonii-loaded nanoparticlesMultiple sclerosisSolid-lipid nanoparticles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.